株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

オピオイド薬の世界市場の将来予測 (2019~2028年)

Global Opioids Drugs Market Forecast 2019-2028

発行 Inkwood Research 商品コード 750061
出版日 ページ情報 英文 168 Pages
納期: 2-3営業日
価格
本日の銀行送金レート: 1USD=108.58円で換算しております。
オピオイド薬の世界市場の将来予測 (2019~2028年) Global Opioids Drugs Market Forecast 2019-2028
出版日: 2020年05月11日 ページ情報: 英文 168 Pages
担当者のコメント
手術や治療管理など麻薬性鎮痛薬として、医療現場では頻繁に用いられるオピオイドの市場規模に着目した調査レポートがm、Inkwood Research社よりリリースされました。モルヒネ/トラマドールなど各種製品別、がん/術後疼痛管理/親権障害など用途別、主要国別に、2028年度までの市場Forecastをまとめております。まずはサンプルページをご依頼ください。
概要

世界のオピオイド薬市場は、2019~2028年にかけて2.48%のCAGRで成長する、と予測されています。市場成長の主な促進要因として、交通事故や外科的処置の増加、重症患者の緩和ケア向けの利用拡大、慢性疼痛の発症件数の増大、更には乱用防止製剤 (ADF) の開発による乱用・誤用・中毒の防止、などが挙げられます。

当レポートでは、世界のオピオイド薬市場の将来展望について分析し、製品の概要や市場の構造、主な市場促進・抑制要因、全体的な市場規模の動向見通し (今後9年間分)、製品別・用途別および地域別の詳細動向、市場競争環境、主要企業のプロファイルなどを調査しております。

第1章 分析範囲・手法

第2章 エグゼクティブサマリー

第3章 市場のダイナミクス

  • 母体市場の分析:ソフトウェア市場
  • 市場の定義
  • 主な市場促進要因
    • 交通事故の増加と外科的処置
    • 重度患者向けの緩和ケアのエスカレート
    • オピオイドの乱用を制限するための乱用抑止製剤 (ADF) の使用
    • 慢性疼痛の発生件数の増加
  • 主な市場抑制要因
    • オピオイドの誤用
    • 厳格な規制の枠組み
    • 地球全体のオピオイド危機
    • オピオイド製造業者に対する訴訟事例の増加
    • オピオイドの過剰摂取に関連した死亡の増加

第4章 主要な分析

  • 主要な投資の考察
  • ポーターのファイブフォース分析
  • 市場機会マトリックス
  • ベンダー情勢
  • 規制の枠組み
  • パイプライン分析
  • オピオイド薬市場での業界動向
  • 技術進歩

第5章 製品別の市場

  • ブプレノルフィン
  • フェンタニル
  • ヒドロコドン
  • モルヒネ
  • オキシコドン
  • トラマドール
  • その他の製品

第6章 用途別市場

  • 疼痛緩和
    • がん疼痛
    • 術後疼痛管理
    • 腰痛
    • 整形外科
    • 線維筋痛症
    • 神経障害
  • 麻酔
  • 咳止め
  • 下痢抑制
  • 依存症治療

第7章 地域別分析

  • 北米
    • 米国
    • カナダ
  • 欧州
    • 英国
    • ドイツ
    • フランス
    • イタリア
    • ロシア
    • ベルギー
    • ポーランド
    • その他の欧州諸国
  • アジア太平洋地域
    • 中国
    • 日本
    • インド
    • 韓国
    • インドネシア
    • タイ
    • ベトナム
    • オーストラリア・ニュージーランド
    • その他のアジア太平洋諸国
  • 他の国々 (RoW)
    • ラテンアメリカ
    • 中東・アフリカ

第8章 企業プロファイル

  • ACURA PHARMACEUTICALS INC
  • ALLERGAN PLC
  • BIODELIVERY SCIENCES INTERNATIONAL INC
  • CIPHER PHARMACEUTICALS INC
  • COLLEGIUM PHARMACEUTICAL INC
  • 第一三共
  • EGALET CORP
  • HIKMA PHARMACEUTICALS PLC
  • INDIVIOR INC
  • JANSSEN PHARMACEUTICALS INC
  • JOHNSON & JOHNSON
  • LANNETT CO. INC
  • LUPIN LTD
  • MYLAN NV
  • PFIZER INC
  • PURDUE PHARMA LP
  • SANOFI-AVENTIS SA
  • SUN PHARMACEUTICAL INDUSTRIES LIMITED(SUN PHARMA)
  • TEVA PHARMACEUTICAL INDUSTRIES LTD
図表

LIST OF TABLES

  • TABLE 1: MARKET SNAPSHOT - OPIOIDS DRUGS
  • TABLE 2: FDA APPROVED OPIOIDS WITH ADF LABELLING
  • TABLE 3: NUMBER OF LAWSUITS CASES SETTLED BY OPIOIDS MANUFACTURING COMPANIES AND PHARMACIES, 2015-2027
  • TABLE 4: LIST OF ER/LA OPIOID BRANDED DRUGS, 2017
  • TABLE 5: LIST OF ER/LA OPIOID GENERIC DRUGS, 2017
  • TABLE 6: CDC GUIDELINES ON PRESCRIBING OPIOIDS
  • TABLE 7: PIPELINE ANALYSIS OF OPIOID DRUGS
  • TABLE 8: GLOBAL OPIOIDS DRUGS MARKET, BY PRODUCT, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 9: GLOBAL OPIOIDS DRUGS MARKET, BY PRODUCT, FORECAST YEARS, 2019-2028 (IN $ MILLION)
  • TABLE 10: GLOBAL BUPRENORPHINE MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 11: GLOBAL BUPRENORPHINE MARKET, BY REGION, FORECAST YEARS, 2019-2028 (IN $ MILLION)
  • TABLE 12: GLOBAL FENTANYL MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 13: GLOBAL FENTANYL MARKET, BY REGION, FORECAST YEARS, 2019-2028 (IN $ MILLION)
  • TABLE 14: GLOBAL HYDROCODONE MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 15: GLOBAL HYDROCODONE MARKET, BY REGION, FORECAST YEARS, 2019-2028 (IN $ MILLION)
  • TABLE 16: GLOBAL MORPHINE MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 17: GLOBAL MORPHINE MARKET, BY REGION, FORECAST YEARS, 2019-2028 (IN $ MILLION)
  • TABLE 18: GLOBAL OXYCODONE MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 19: GLOBAL OXYCODONE MARKET, BY REGION, FORECAST YEARS, 2019-2028 (IN $ MILLION)
  • TABLE 20: GLOBAL TRAMADOL MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 21: GLOBAL TRAMADOL MARKET, BY REGION, FORECAST YEARS, 2019-2028 (IN $ MILLION)
  • TABLE 22: GLOBAL OTHER PRODUCTS MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 23: GLOBAL OTHER PRODUCTS MARKET, BY REGION, FORECAST YEARS, 2019-2028 (IN $ MILLION)
  • TABLE 24: GLOBAL OPIOIDS DRUGS MARKET, BY APPLICATION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 25: GLOBAL OPIOIDS DRUGS MARKET, BY APPLICATION, FORECAST YEARS, 2019-2028 (IN $ MILLION)
  • TABLE 26: GLOBAL PAIN RELIEF MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 27: GLOBAL PAIN RELIEF MARKET, BY REGION, FORECAST YEARS, 2019-2028 (IN $ MILLION)
  • TABLE 28: GLOBAL PAIN RELIEF MARKET, BY TYPE, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 29: GLOBAL PAIN RELIEF MARKET, BY TYPE, FORECAST YEARS, 2019-2028 (IN $ MILLION)
  • TABLE 30: GLOBAL CANCER PAIN MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 31: GLOBAL CANCER PAIN MARKET, BY REGION, FORECAST YEARS, 2019-2028 (IN $ MILLION)
  • TABLE 32: GLOBAL POSTOPERATIVE PAIN MANAGEMENT MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 33: GLOBAL POSTOPERATIVE PAIN MANAGEMENT MARKET, BY REGION, FORECAST YEARS, 2019-2028 (IN $ MILLION)
  • TABLE 34: GLOBAL LOW BACK PAIN MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 35: GLOBAL LOW BACK PAIN MARKET, BY REGION, FORECAST YEARS, 2019-2028 (IN $ MILLION)
  • TABLE 36: GLOBAL ORTHOPEDIC MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 37: GLOBAL ORTHOPEDIC MARKET, BY REGION, FORECAST YEARS, 2019-2028 (IN $ MILLION)
  • TABLE 38: GLOBAL FIBROMYALGIA MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 39: GLOBAL FIBROMYALGIA MARKET, BY REGION, FORECAST YEARS, 2019-2028 (IN $ MILLION)
  • TABLE 40: GLOBAL NEUROPATHIC MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 41: GLOBAL NEUROPATHIC MARKET, BY REGION, FORECAST YEARS, 2019-2028 (IN $ MILLION)
  • TABLE 42: GLOBAL ANESTHESIA MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 43: GLOBAL ANESTHESIA MARKET, BY REGION, FORECAST YEARS, 2019-2028 (IN $ MILLION)
  • TABLE 44: GLOBAL COUGH SUPPRESSION MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 45: GLOBAL COUGH SUPPRESSION MARKET, BY REGION, FORECAST YEARS, 2019-2028 (IN $ MILLION)
  • TABLE 46: GLOBAL DIARRHEA SUPPRESSION MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 47: GLOBAL DIARRHEA SUPPRESSION MARKET, BY REGION, FORECAST YEARS, 2019-2028 (IN $ MILLION)
  • TABLE 48: GLOBAL DEADDICTION MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 49: GLOBAL DEADDICTION MARKET, BY REGION, FORECAST YEARS, 2019-2028 (IN $ MILLION)
  • TABLE 50: GLOBAL OPIOIDS DRUGS MARKET, BY GEOGRAPHY, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 51: GLOBAL OPIOIDS DRUGS MARKET, BY GEOGRAPHY, FORECAST YEARS, 2019-2028 (IN $ MILLION)
  • TABLE 52: NORTH AMERICA OPIOIDS DRUGS MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 53: NORTH AMERICA OPIOIDS DRUGS MARKET, BY COUNTRY, FORECAST YEARS, 2019-2028 (IN $ MILLION)
  • TABLE 54: EUROPE OPIOIDS DRUGS MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 55: EUROPE OPIOIDS DRUGS MARKET, BY COUNTRY, FORECAST YEARS, 2019-2028 (IN $ MILLION)
  • TABLE 56: ASIA PACIFIC OPIOIDS DRUGS MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 57: ASIA PACIFIC OPIOIDS DRUGS MARKET, BY COUNTRY, FORECAST YEARS, 2019-2028 (IN $ MILLION)
  • TABLE 58: REST OF WORLD OPIOIDS DRUGS MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 59: REST OF WORLD OPIOIDS DRUGS MARKET, BY REGION, FORECAST YEARS, 2019-2028 (IN $ MILLION)

LIST OF FIGURES

  • FIGURE 1: KEY INVESTMENT INSIGHTS
  • FIGURE 2: PORTER'S FIVE FORCE ANALYSIS
  • FIGURE 3: OPPORTUNITY MATRIX
  • FIGURE 4: VENDOR LANDSCAPE
  • FIGURE 5: GLOBAL OPIOIDS DRUGS MARKET, GROWTH POTENTIAL, BY PRODUCT, IN 2019
  • FIGURE 6: GLOBAL OPIOIDS DRUGS MARKET, BY BUPRENORPHINE, 2019-2028 (IN $ MILLION)
  • FIGURE 7: GLOBAL OPIOIDS DRUGS MARKET, BY FENTANYL, 2019-2028 (IN $ MILLION)
  • FIGURE 8: GLOBAL OPIOIDS DRUGS MARKET, BY HYDROCODONE, 2019-2028 (IN $ MILLION)
  • FIGURE 9: GLOBAL OPIOIDS DRUGS MARKET, BY MORPHINE, 2019-2028 (IN $ MILLION)
  • FIGURE 10: GLOBAL OPIOIDS DRUGS MARKET, BY OXYCODONE, 2019-2028 (IN $ MILLION)
  • FIGURE 11: GLOBAL OPIOIDS DRUGS MARKET, BY TRAMADOL, 2019-2028 (IN $ MILLION)
  • FIGURE 12: GLOBAL OPIOIDS DRUGS MARKET, BY OTHER PRODUCTS, 2019-2028 (IN $ MILLION)
  • FIGURE 13: GLOBAL OPIOIDS DRUGS MARKET, GROWTH POTENTIAL, BY APPLICATION, IN 2019
  • FIGURE 14: GLOBAL OPIOIDS DRUGS MARKET, BY PAIN RELIEF, 2019-2028 (IN $ MILLION)
  • FIGURE 15: GLOBAL OPIOIDS DRUGS MARKET, BY CANCER PAIN, 2019-2028 (IN $ MILLION)
  • FIGURE 16: GLOBAL OPIOIDS DRUGS MARKET, BY POSTOPERATIVE PAIN MANAGEMENT, 2019-2028 (IN $ MILLION)
  • FIGURE 17: GLOBAL OPIOIDS DRUGS MARKET, BY LOW BACK PAIN, 2019-2028 (IN $ MILLION)
  • FIGURE 18: GLOBAL OPIOIDS DRUGS MARKET, BY ORTHOPEDIC, 2019-2028 (IN $ MILLION)
  • FIGURE 19: GLOBAL OPIOIDS DRUGS MARKET, BY FIBROMYALGIA, 2019-2028 (IN $ MILLION)
  • FIGURE 20: GLOBAL OPIOIDS DRUGS MARKET, BY NEUROPATHIC, 2019-2028 (IN $ MILLION)
  • FIGURE 21: GLOBAL OPIOIDS DRUGS MARKET, BY ANESTHESIA, 2019-2028 (IN $ MILLION)
  • FIGURE 22: GLOBAL OPIOIDS DRUGS MARKET, BY COUGH SUPPRESSION, 2019-2028 (IN $ MILLION)
  • FIGURE 23: GLOBAL OPIOIDS DRUGS MARKET, BY DIARRHEA SUPPRESSION, 2019-2028 (IN $ MILLION)
  • FIGURE 24: GLOBAL OPIOIDS DRUGS MARKET, BY DEADDICTION, 2019-2028 (IN $ MILLION)
  • FIGURE 25: NORTH AMERICA OPIOIDS DRUGS MARKET, REGIONAL OUTLOOK, 2019 & 2028 (IN %)
  • FIGURE 26: UNITED STATES OPIOIDS DRUGS MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 27: CANADA OPIOIDS DRUGS MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 28: EUROPE OPIOIDS DRUGS MARKET, REGIONAL OUTLOOK, 2019 & 2028 (IN %)
  • FIGURE 29: UNITED KINGDOM OPIOIDS DRUGS MARKET, 2019-2028 (IN $ MILLION)
  • FIGURE 30: GERMANY OPIOIDS DRUGS MARKET, 2019-2028 (IN $ MILLION)
  • FIGURE 31: FRANCE OPIOIDS DRUGS MARKET, 2019-2028 (IN $ MILLION)
  • FIGURE 32: ITALY OPIOIDS DRUGS MARKET, 2019-2028 (IN $ MILLION)
  • FIGURE 33: RUSSIA OPIOIDS DRUGS MARKET, 2019-2028 (IN $ MILLION)
  • FIGURE 34: BELGIUM OPIOIDS DRUGS MARKET, 2019-2028 (IN $ MILLION)
  • FIGURE 35: POLAND OPIOIDS DRUGS MARKET, 2019-2028 (IN $ MILLION)
  • FIGURE 36: REST OF EUROPE OPIOIDS DRUGS MARKET, 2019-2028 (IN $ MILLION)
  • FIGURE 37: ASIA PACIFIC OPIOIDS DRUGS MARKET, REGIONAL OUTLOOK, 2019 & 2028 (IN %)
  • FIGURE 38: CHINA OPIOIDS DRUGS MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 39: JAPAN OPIOIDS DRUGS MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 40: INDIA OPIOIDS DRUGS MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 41: SOUTH KOREA OPIOIDS DRUGS MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 42: INDONESIA OPIOID DRUGS MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 43: THAILAND OPIOID DRUGS MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 44: VIETNAM OPIOID DRUGS MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 45: AUSTRALIA & NEW ZEALAND OPIOID DRUGS MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 46: REST OF WORLD OPIOIDS DRUGS MARKET, REGIONAL OUTLOOK, 2019 & 2028 (IN %)
  • FIGURE 47: LATIN AMERICA OPIOIDS DRUGS MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 48: MIDDLE EAST AND AFRICA OPIOIDS DRUGS MARKET, 2020-2028 (IN $ MILLION)
目次
Product Code: 22680

KEY FINDINGS

The global opioids drugs market is anticipated to grow at a CAGR of 2.48% over the forecast period of 2019-2028. The major factors augmenting the global market growth are the growing number of road accidents and surgical procedures, increasing palliative care for patients going through intense suffering, and growing incidence of chronic pain.

MARKET INSIGHTS

Opioids are majorly used to relieve moderate to severe pain, though they can occasionally be used to treat coughing and diarrhea. The opioid drugs are associated with side effects, a high risk of dependence, and addiction. Opioid addiction, overdose, and abuse, are serious health concerns across the world. Novel opioid formulation to reduce the risk of abuse is driving the market growth. The development of abuse-deterrent formulations (ADF) of opioid medications is likely to decrease abuse, misuse, and addiction to opioid drugs. The ADF is designed in such a way that the drug becomes resistant to physical manipulation.

Opioid misuse is one of the major factors restraining market growth. Opioid misuse includes abuse of prescription pain relievers or the use of heroin. The existing market players are focusing on developing innovative dosage forms, which will increase drug efficiency at a minimum dose.

REGIONAL INSIGHTS

The global opioids drugs market has been segregated into North America, Europe, Asia Pacific, and the Rest of the World to analyze the potential of the respective markets. The region of North America holds the largest market share in terms of revenue in 2019. The high rate of approval and launch of new abuse-deterrent formulation (ADF) of the opioid drug is contributing to market growth in the region.

COMPETITIVE INSIGHTS

The market competition is high in the generic space owing to major companies supplying various opioid drugs. Some of the prominent existing players in the market are Daiichi Sankyo, Inc, Teva Pharmaceutical Industries Ltd, Hikma Pharmaceuticals, Janssen Pharmaceuticals, Inc, Lupin Ltd, Johnson & Johnson, etc.

Our report offerings include:

  • Explore key findings of the overall market
  • Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
  • Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
  • Market Segmentation cater to a thorough assessment of key segments with their market estimations
  • Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
  • Key analytics: Porter's Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
  • Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
  • Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments

TABLE OF CONTENTS

1. RESEARCH SCOPE & METHODOLOGY

  • 1.1. STUDY OBJECTIVES
  • 1.2. SCOPE OF STUDY
  • 1.3. METHODOLOGY
  • 1.4. ASSUMPTIONS & LIMITATIONS

2. EXECUTIVE SUMMARY

  • 2.1. MARKET SIZE & ESTIMATES
  • 2.2. MARKET OVERVIEW

3. MARKET DYNAMICS

  • 3.1. MARKET DEFINITION
  • 3.2. KEY DRIVERS
    • 3.2.1. INCREASING ROAD ACCIDENTS AND SURGICAL PROCEDURES
    • 3.2.2. ESCALATING PALLIATIVE CARE FOR PATIENTS SUFFERING INTENSELY
    • 3.2.3. USAGE OF ABUSE DETERRENT FORMULATIONS TO RESTRICT THE OPIOID ABUSE
    • 3.2.4. GROWING OCCURRENCE OF CHRONIC PAIN
  • 3.3. KEY RESTRAINTS
    • 3.3.1. MISUSE OF OPIOIDS
    • 3.3.2. STRINGENT REGULATORY FRAMEWORK
    • 3.3.3. OPIOID CRISIS ACROSS THE GLOBE
    • 3.3.4. INCREASING NUMBER OF LAWSUITS CASES AGAINST OPIOIDS MANUFACTURERS
    • 3.3.5. RISING OCCURRENCE OF DEATHS RELATED TO OPIOID OVERDOSE

4. KEY ANALYTICS

  • 4.1. KEY INVESTMENT INSIGHTS
  • 4.2. PORTER'S FIVE FORCE ANALYSIS
    • 4.2.1. BUYER POWER
    • 4.2.2. SUPPLIER POWER
    • 4.2.3. SUBSTITUTION
    • 4.2.4. NEW ENTRANTS
    • 4.2.5. INDUSTRY RIVALRY
  • 4.3. OPPORTUNITY MATRIX
  • 4.4. VENDOR LANDSCAPE
  • 4.5. REGULATORY FRAMEWORK
  • 4.6. PIPELINE ANALYSIS
  • 4.7. INDUSTRY EVENTS IN OPIOID DRUGS MARKET
  • 4.8. TECHNOLOGICAL ADVANCEMENT

5. MARKET BY PRODUCT

  • 5.1. BUPRENORPHINE
  • 5.2. FENTANYL
  • 5.3. HYDROCODONE
  • 5.4. MORPHINE
  • 5.5. OXYCODONE
  • 5.6. TRAMADOL
  • 5.7. OTHER PRODUCTS

6. MARKET BY APPLICATION

  • 6.1. PAIN RELIEF
    • 6.1.1. CANCER PAIN
    • 6.1.2. POSTOPERATIVE PAIN MANAGEMENT
    • 6.1.3. LOW BACK PAIN
    • 6.1.4. ORTHOPEDIC
    • 6.1.5. FIBROMYALGIA
    • 6.1.6. NEUROPATHIC
  • 6.2. ANESTHESIA
  • 6.3. COUGH SUPPRESSION
  • 6.4. DIARRHEA SUPPRESSION
  • 6.5. DEADDICTION

7. GEOGRAPHICAL ANALYSIS

  • 7.1. NORTH AMERICA
    • 7.1.1. UNITED STATES
    • 7.1.2. CANADA
  • 7.2. EUROPE
    • 7.2.1. UNITED KINGDOM
    • 7.2.2. GERMANY
    • 7.2.3. FRANCE
    • 7.2.4. ITALY
    • 7.2.5. RUSSIA
    • 7.2.6. BELGIUM
    • 7.2.7. POLAND
    • 7.2.8. REST OF EUROPE
  • 7.3. ASIA PACIFIC
    • 7.3.1. CHINA
    • 7.3.2. JAPAN
    • 7.3.3. INDIA
    • 7.3.4. SOUTH KOREA
    • 7.3.5. INDONESIA
    • 7.3.6. THAILAND
    • 7.3.7. VIETNAM
    • 7.3.8. AUSTRALIA & NEW ZEALAND
    • 7.3.9. REST OF ASIA PACIFIC
  • 7.4. REST OF WORLD
    • 7.4.1. LATIN AMERICA
    • 7.4.2. MIDDLE EAST AND AFRICA

8. COMPANY PROFILES

  • 8.1. ACURA PHARMACEUTICALS INC
  • 8.2. ALLERGAN PLC
  • 8.3. BIODELIVERY SCIENCES INTERNATIONAL INC
  • 8.4. CIPHER PHARMACEUTICALS INC
  • 8.5. COLLEGIUM PHARMACEUTICAL INC
  • 8.6. DAIICHI SANKYO INC
  • 8.7. EGALET CORP
  • 8.8. HIKMA PHARMACEUTICALS PLC
  • 8.9. INDIVIOR INC
  • 8.10. JANSSEN PHARMACEUTICALS INC
  • 8.11. JOHNSON & JOHNSON
  • 8.12. LANNETT CO. INC
  • 8.13. LUPIN LTD
  • 8.14. MYLAN NV
  • 8.15. PFIZER INC
  • 8.16. PURDUE PHARMA LP
  • 8.17. SANOFI-AVENTIS S.A
  • 8.18. SUN PHARMACEUTICAL INDUSTRIES LIMITED (SUN PHARMA)
  • 8.19. TEVA PHARMACEUTICAL INDUSTRIES LTD